X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (3731) 3731
Book Review (422) 422
Publication (245) 245
Newsletter (196) 196
Magazine Article (15) 15
Conference Proceeding (14) 14
Book Chapter (2) 2
Paper (2) 2
Dissertation (1) 1
Newspaper Article (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (3040) 3040
pravastatin (2747) 2747
humans (2254) 2254
male (1710) 1710
pharmacology & pharmacy (1628) 1628
female (1211) 1211
animals (1137) 1137
statins (1078) 1078
pravastatin - pharmacology (1033) 1033
simvastatin (1001) 1001
hydroxymethylglutaryl-coa reductase inhibitors - pharmacology (935) 935
middle aged (908) 908
cholesterol (760) 760
hydroxymethylglutaryl-coa reductase inhibitors - therapeutic use (679) 679
atorvastatin (673) 673
adult (662) 662
aged (660) 660
rats (552) 552
pravastatin - therapeutic use (522) 522
hypercholesterolemia (503) 503
prevention (439) 439
lovastatin (435) 435
anticholesteremic agents - pharmacology (426) 426
cardiac & cardiovascular systems (421) 421
hypercholesterolemia - drug therapy (418) 418
atherosclerosis (401) 401
cholesterol - blood (395) 395
atorvastatin calcium (364) 364
coronary-heart-disease (349) 349
anticholesteremic agents - therapeutic use (344) 344
risk (339) 339
cholesterol, ldl - blood (329) 329
simvastatin - pharmacology (327) 327
antilipemic agents (323) 323
peripheral vascular disease (310) 310
coa reductase inhibitors (309) 309
mice (307) 307
risk factors (303) 303
dose-response relationship, drug (298) 298
heptanoic acids - pharmacology (293) 293
drug interactions (285) 285
abridged index medicus (279) 279
research (274) 274
treatment outcome (269) 269
pharmacokinetics (263) 263
cells, cultured (261) 261
hmg-coa reductase (261) 261
hydroxymethylglutaryl-coa reductase inhibitors - adverse effects (261) 261
hydroxymethylglutaryl-coa reductase inhibitors - administration & dosage (257) 257
pyrroles - pharmacology (255) 255
therapy (254) 254
lipids (252) 252
analysis (249) 249
myocardial-infarction (249) 249
statin (247) 247
disease (243) 243
lovastatin - pharmacology (242) 242
drug therapy (234) 234
fluvastatin (226) 226
rosuvastatin (225) 225
pravastatin - administration & dosage (221) 221
hydroxymethylglutaryl-coa reductase inhibitors (218) 218
medicine & public health (215) 215
double-blind method (213) 213
time factors (211) 211
drugs (207) 207
events (205) 205
expression (199) 199
inflammation (199) 199
lipids - blood (197) 197
rats, sprague-dawley (197) 197
men (194) 194
triglycerides - blood (194) 194
simvastatin - therapeutic use (193) 193
biochemistry & molecular biology (189) 189
metabolism (189) 189
hydroxymethylglutaryl-coa reductase inhibitors - pharmacokinetics (187) 187
hypercholesterolemia - blood (187) 187
coenzyme-a reductase (182) 182
efficacy (181) 181
liver - metabolism (181) 181
pravastatin - pharmacokinetics (180) 180
heptanoic acids - therapeutic use (178) 178
pharmacology/toxicology (177) 177
pyrroles - therapeutic use (167) 167
safety (164) 164
nitric-oxide synthase (163) 163
medicine, research & experimental (159) 159
hyperlipidemias - drug therapy (157) 157
pharmacology (157) 157
c-reactive protein (156) 156
coronary heart disease (156) 156
mortality (155) 155
rosuvastatin calcium (155) 155
cardiovascular disease (150) 150
in-vitro (150) 150
cardiovascular agents (149) 149
care and treatment (149) 149
cholesterol, hdl - blood (146) 146
disease models, animal (146) 146
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (3803) 3803
Japanese (54) 54
French (23) 23
Chinese (19) 19
Spanish (14) 14
German (11) 11
Russian (8) 8
Italian (7) 7
Portuguese (3) 3
Polish (2) 2
Swedish (2) 2
Danish (1) 1
Dutch (1) 1
Slovenian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Drug Metabolism and Disposition, ISSN 0090-9556, 09/2012, Volume 40, Issue 9, pp. 1744 - 1756
Interindividual variability in activity of uptake transporters is evident in vivo, yet limited data exist in vitro, confounding in vitro-in vivo extrapolation.... 
DRUG TRANSPORTERS | IN-VITRO CLEARANCE | CRYOPRESERVED HUMAN HEPATOCYTES | HMG-COA REDUCTASE | PHARMACOLOGY & PHARMACY | ANION TRANSPORTING POLYPEPTIDES | HEPATIC-UPTAKE | HEALTHY-VOLUNTEERS | METABOLIC ENZYMES | RECEPTOR ANTAGONIST | PREDICTION | Antihypertensive Agents - pharmacology | Tetrazoles - pharmacology | Species Specificity | Valsartan | Hypoglycemic Agents - metabolism | Benzoates - metabolism | Humans | Antihypertensive Agents - metabolism | Hepatocytes - metabolism | Angiotensin II Type 1 Receptor Blockers - pharmacology | Angiotensin II Type 1 Receptor Blockers - metabolism | Organic Anion Transporters - metabolism | Pyrimidines - metabolism | Quinolines - pharmacology | Tetrazoles - metabolism | Carbamates - metabolism | Dose-Response Relationship, Drug | Fluorobenzenes - pharmacology | Drug Interactions | Hydroxymethylglutaryl-CoA Reductase Inhibitors - metabolism | Biological Transport | Piperidines - pharmacology | Hepatocytes - drug effects | Carbamates - pharmacology | Pravastatin - pharmacology | Fluorobenzenes - metabolism | Piperidines - metabolism | Pravastatin - metabolism | Valine - analogs & derivatives | Rats | Rosuvastatin Calcium | Pyrimidines - pharmacology | Sulfonamides - pharmacology | Hypoglycemic Agents - pharmacology | Quinolines - metabolism | Animals | Hydroxymethylglutaryl-CoA Reductase Inhibitors - pharmacology | Valine - metabolism | Models, Biological | Benzimidazoles - metabolism | Sulfonamides - metabolism | Benzoates - pharmacology | Benzimidazoles - pharmacology | Kinetics | Valine - pharmacology | Organic Anion Transporters - drug effects | Index Medicus
Journal Article
Drug Metabolism and Disposition, ISSN 0090-9556, 08/2007, Volume 35, Issue 8, pp. 1308 - 1314
Hepatic uptake carriers of the organic anion-transporting peptide (OATP) family of solute carriers are more and more recognized as being involved in hepatic... 
RAT | SEVERE RHABDOMYOLYSIS | COMBINATION THERAPY | LIVER | PHARMACOLOGY & PHARMACY | CERIVASTATIN | HEPATIC-UPTAKE | TRANSPLANT RECIPIENTS | ROSUVASTATIN | POLYPEPTIDE | FAMILY | Organic Anion Transporters, Sodium-Independent - genetics | Fatty Acids, Monounsaturated - pharmacology | Cricetulus | Hypolipidemic Agents - metabolism | Hypoglycemic Agents - metabolism | Taurocholic Acid - metabolism | Humans | Hepatocytes - metabolism | Simvastatin - pharmacology | Organic Anion Transporters - metabolism | Chromans - metabolism | Hepatocytes - cytology | Indoles - metabolism | Organic Anion Transporters - genetics | Drug Interactions | Anticholesteremic Agents - metabolism | Chromans - pharmacology | Fatty Acids, Monounsaturated - metabolism | Organic Anion Transporters, Sodium-Independent - metabolism | Indoles - pharmacology | Biological Transport - drug effects | Thiazolidinediones - pharmacology | Hepatocytes - drug effects | Solute Carrier Organic Anion Transporter Family Member 1B3 | CHO Cells | Pravastatin - pharmacology | Recombinant Proteins - metabolism | Taurocholic Acid - pharmacology | Cell Line | Cricetinae | Pravastatin - metabolism | Simvastatin - metabolism | Gemfibrozil - pharmacokinetics | Gemfibrozil - pharmacology | Hypolipidemic Agents - pharmacology | Thiazolidinediones - metabolism | Hypoglycemic Agents - pharmacology | Animals | Estrone - analogs & derivatives | Estrone - metabolism | Protein Binding | Fatty Acids, Monounsaturated - pharmacokinetics | Indoles - pharmacokinetics | Kinetics | Solute Carrier Organic Anion Transporter Family Member 1b1 | Anticholesteremic Agents - pharmacology | Gemfibrozil - metabolism | Index Medicus
Journal Article
Journal of Pharmacy and Pharmacology, ISSN 0022-3573, 07/2016, Volume 68, Issue 7, pp. 883 - 889
Journal Article
Journal Article
European Journal of Pharmacology, ISSN 0014-2999, 10/2015, Volume 764, pp. 283 - 291
The present study was carried out to evaluate the protective effect of different statins on isoproterenol (ISO) induced myocardial necrosis. Atorvastatin,... 
Fluvastatin | Simvastatin | Atorvastatin | Rosuvastatin | Myocardial necrosis | Isoproterenol | Pravastatin | CHRONIC HEART-FAILURE | COENZYME-A REDUCTASE | CHOLESTEROL | INFARCTION | PLASMA | PHARMACOLOGY & PHARMACY | RAT-HEART | LIPOPROTEINS | STATIN TREATMENT | Necrosis - drug therapy | Myocardial Infarction - chemically induced | Simvastatin - therapeutic use | Fatty Acids, Monounsaturated - pharmacology | Rosuvastatin Calcium - therapeutic use | Rats, Wistar | Atorvastatin Calcium - pharmacology | Glutathione - metabolism | Cholesterol - blood | Male | Simvastatin - pharmacology | Necrosis - pathology | Cardiotonic Agents - therapeutic use | Fatty Acids, Monounsaturated - therapeutic use | Myocardial Infarction - pathology | Myocardium - metabolism | Indoles - pharmacology | Pravastatin - therapeutic use | Atorvastatin Calcium - therapeutic use | Superoxide Dismutase - metabolism | Pravastatin - pharmacology | Blood Glucose - analysis | Rosuvastatin Calcium - pharmacology | Adenosine Triphosphatases - metabolism | Myocardium - pathology | Necrosis - metabolism | Cardiotonic Agents - pharmacology | Myocardial Infarction - metabolism | Necrosis - chemically induced | Catalase - metabolism | Animals | Hydroxymethylglutaryl-CoA Reductase Inhibitors - pharmacology | Myocardial Infarction - drug therapy | Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use | Isoproterenol - pharmacology | Triglycerides - blood | Indoles - therapeutic use | Isoproterenol - therapeutic use | Antioxidants | Pharmacy | Drugstores | Glucose | Comparative analysis | Statins | Dextrose | Necrosis | Index Medicus
Journal Article
Inflammation, ISSN 0360-3997, 10/2014, Volume 37, Issue 5, pp. 1355 - 1365
Our aim was to investigate the effects of four different statins on acute lung inflammation induced by cigarette smoke (CS). C57BL/6 male mice were divided... 
lung | Pathology | Medicine & Public Health | inflammation | statins | Rheumatology | Internal Medicine | Pharmacology/Toxicology | cigarette smoke | mice | oxidative stress | NADPH OXIDASE | COA REDUCTASE INHIBITORS | LIPID-PEROXIDATION | INJURY | DEFICIENT MICE | INOS | IMMUNOLOGY | HUMAN MONOCYTES | CELL BIOLOGY | LEUKOTRIENE B-4 | NITRIC-OXIDE | INDUCED PULMONARY-HYPERTENSION | Simvastatin - therapeutic use | Heptanoic Acids - therapeutic use | Oxidative Stress - physiology | Male | Simvastatin - pharmacology | Fluorobenzenes - pharmacology | Inflammation Mediators - metabolism | Anti-Inflammatory Agents - therapeutic use | Inhalation Exposure - adverse effects | Inflammation Mediators - antagonists & inhibitors | Lung - metabolism | Pyrroles - therapeutic use | Pravastatin - therapeutic use | Heptanoic Acids - pharmacology | Pravastatin - pharmacology | Lung - pathology | Anti-Inflammatory Agents - pharmacology | Mice, Inbred C57BL | Smoking - drug therapy | Rosuvastatin Calcium | Antioxidants - pharmacology | Pyrimidines - pharmacology | Sulfonamides - pharmacology | Atorvastatin Calcium | Smoking - metabolism | Antioxidants - therapeutic use | Pyrroles - pharmacology | Animals | Hydroxymethylglutaryl-CoA Reductase Inhibitors - pharmacology | Sulfonamides - therapeutic use | Pyrimidines - therapeutic use | Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use | Lung - drug effects | Smoking - pathology | Mice | Oxidative Stress - drug effects | Fluorobenzenes - therapeutic use | Oxidative stress | Complications and side effects | Inflammation | Research | Cigarette smoke | Risk factors | Index Medicus
Journal Article
European Heart Journal, ISSN 0195-668X, 09/2012, Volume 33, Issue 17, pp. 2151 - 2162
Aims CYP3A4-metabolized statins can influence the pharmacodynamic effect of clopidogrel. We sought to assess the impact of switching to a... 
Atorvastatin | Clopidogrel | Platelet | Non-CYP3A4-metabolized statin | High platelet reactivity | REDUCTASE INHIBITORS | CARDIAC & CARDIOVASCULAR SYSTEMS | ABCB1 | GENETIC-VARIANTS | CYP2C19 | CYTOCHROME-P450 3A4 | CLINICAL PHARMACOGENETICS | DRUG-DRUG INTERACTION | TRIAL | PERCUTANEOUS CORONARY INTERVENTION | Prospective Studies | Ticlopidine - therapeutic use | Heptanoic Acids - therapeutic use | Humans | Middle Aged | Calcium Channel Blockers - therapeutic use | Cytochrome P-450 CYP3A - physiology | Male | Pyrimidines - metabolism | Fluorobenzenes - pharmacology | Cytochrome P-450 CYP3A - genetics | Platelet Aggregation Inhibitors - pharmacology | Female | Aspirin - therapeutic use | Platelet Aggregation - drug effects | Drug Therapy, Combination | Platelet Aggregation Inhibitors - therapeutic use | Pyrroles - therapeutic use | Pravastatin - therapeutic use | Heptanoic Acids - pharmacology | Pravastatin - pharmacology | Fluorobenzenes - metabolism | Pravastatin - metabolism | Rosuvastatin Calcium | Genotype | Coronary Artery Disease - drug therapy | Pyrimidines - pharmacology | Sulfonamides - pharmacology | Ticlopidine - analogs & derivatives | Adenosine Diphosphate - pharmacology | Pyrroles - pharmacology | Hydroxymethylglutaryl-CoA Reductase Inhibitors - pharmacology | Sulfonamides - therapeutic use | Pyrimidines - therapeutic use | Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use | Sulfonamides - metabolism | Drug Substitution | Fluorobenzenes - therapeutic use | Percutaneous Coronary Intervention | Index Medicus
Journal Article
The American Journal of Gastroenterology, ISSN 0002-9270, 04/2008, Volume 103, Issue 4, pp. 825 - 837
Journal Article
Journal Article
Journal of the National Cancer Institute, ISSN 0027-8874, 11/2008, Volume 100, Issue 21, pp. 1511 - 1518
Journal Article